구인두암에서 인간 유두종 바이러스 유전자 검사와 p16 과발현의 임상적 의의

초록

Background and Objectives Oropharyngeal squamous cell carcinoma (OPSCC) can becaused by human papilloma virus (HPV) infection or other factors like smoking. The 8th Edi tion of the AJCC Cancer Staging Manual recommends different staging and treatment ap proaches based on etiology. Despite criticisms of its low specificity, the current guidelines sug gest using p16 immunohistochemistry (IHC) as a surrogate marker for the HPV-related OPSCC. This study assessed the reliability of p16 as a surrogate marker by correlating the survival ratesof OPSCC patients with the results of p16 IHC and HPV-DNA testing. Subjects and Method A retrospective analysis was performed on patients treated for tonsilsquamous cell carcinoma at a tertiary medical institution between 1994 and 2018. All patientsunderwent p16 immunostaining and HPV-DNA chip tests. Out of 88 patients, 17 were exclud ed due to insufficient data or secondary primary cancer, leaving 71 patients. Results Among the 71 patients, 51 were p16 positive and 49 were HPV-DNA positive; bothtests were associated with extended survival. However, discrepancies were noted in 18 patients:specifically, 11 patients were p16 positive but HPV-DNA negative, displaying a different sur vival pattern compared to HPV-associated and non-HPV-associated patients. Conclusion Both p16 immunostaining and HPV-DNA testing have their pros and cons. p16immunostaining is cost-effective but has lower specificity. The study found discrepancies in18 patients, suggesting that relying solely on p16 immunostaining may have limitations. Itwould be advisable to complement it with additional tests like the HPV-DNA chip test to pre dict the disease’s prognosis more accurately.

키워드